| Not Yet Recruiting | A Phase I Clinical Trial of Absorbed Acellular Pertussis (Two-Component) Diphtheria-Tetanus Combined Vaccine ( NCT07492303 | Changchun BCHT Biotechnology Co. | Phase 1 |
| Not Yet Recruiting | Phase I/II Clinical Trial of Diphtheria-Tetanus-Pertussis (Reduced Dose) Vaccine NCT07418372 | Institute of Medical Biology, Chinese Academy of Medical Sciences | Phase 1 / Phase 2 |
| Recruiting | A Phase II/III Study to Evaluate the Immunogenicity, Safety and Lot-to-lot Consistency of LBVD, a Fully Liquid NCT06947499 | LG Chem | Phase 2 / Phase 3 |
| Active Not Recruiting | A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component) NCT06708286 | CanSino Biologics Inc. | Phase 2 / Phase 3 |
| Completed | PFAS Exposure and Immune Response to Vaccination in Adults NCT06588530 | Rutgers, The State University of New Jersey | Phase 4 |
| Not Yet Recruiting | Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healt NCT06618196 | LG Chem | Phase 2 |
| Recruiting | Safety and Immunogenicity of DTaP-IPV/Hib Pentavalent Vaccine in Chinese 2-month-old Infants NCT06605755 | Jiangsu Province Centers for Disease Control and Prevention | N/A |
| Recruiting | Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine NCT06184542 | Institute of Medical Biology, Chinese Academy of Medical Sciences | Phase 1 |
| Active Not Recruiting | A Clinical Trial of Adsorbed Cell-free DPT Vaccine (5-component) (for People Aged 6 Years and Above) NCT06056050 | CanSino Biologics Inc. | Phase 1 |
| Unknown | A Study to Evaluate Safety and Immunogenicity of APV006 in Healthy Adults NCT05952596 | LG Chem | Phase 1 |
| Unknown | Study to Evaluate the Immunogenicity and Safety of LBVD(Hexavalent Vaccine), Given to Healthy Infants at Prima NCT05457946 | LG Chem | Phase 2 / Phase 3 |
| Unknown | Immunogenicity and Safety of Vaccine Against Tetanus and Diphtheria. NCT05480462 | IBSS Biomed S.A. | Phase 3 |
| Active Not Recruiting | A Phase 3 Study of BIBP Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Adsor NCT05091619 | China National Biotec Group Company Limited | Phase 3 |
| Completed | A Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK)'s Infanrix Hexa Vaccine (DTPa-HBV-IPV/H NCT04535037 | GlaxoSmithKline | Phase 4 |
| Completed | Phase I Clinical Trial of Diphtheria, Tetanus and Acellular Pertussis (Three Components) Combined Vaccine, Ads NCT04099303 | CanSino Biologics Inc. | Phase 1 |
| Unknown | To Evaluate the Immunogenicity and Safety of DTaP-IPV Vaccine Administered as a Boosting Dose to Healthy Child NCT04618640 | Boryung Biopharma Co., Ltd. | Phase 3 |
| Unknown | Safety and Immunogenicity of Hexavalent Vaccine(DTwP-HepB-IPV-Hib) in Healthy Infants NCT04073459 | LG Chem | Phase 2 |
| Completed | Sero-epidemiological Survey of England in 2019/2020 - COVID-19 NCT04061382 | University of Oxford | — |
| Unknown | A Study to Evaluate the Safety and Efficacy(Immunogenicity) of GC3111 in Healthy Adults NCT04238975 | Green Cross Corporation | Phase 2 |
| Unknown | A Phase IV Study to Assess the Safety of EupentaTM Inj NCT04056728 | LG Chem | Phase 4 |
| Completed | Evaluate the Safety Pharmacokinetics of a Human Monoclonal Antibody S315 Against Diphtheria Toxin in Healthy S NCT04075175 | MassBiologics | Phase 1 |
| Completed | Confirmatory Study of BK1310 in Healthy Infants NCT03891758 | Tanabe Pharma Corporation | Phase 3 |
| Completed | Study on the Safety and Immunogenicity of Boostrix Vaccine in Pregnant Malian Women and Their Infants NCT03589768 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Increasing Vaccine Uptake Among Veterans at the Atlanta VA Health Care System NCT03950986 | Atlanta VA Medical Center | N/A |
| Completed | Evaluation of an Infant Immunization Encouragement Program in Nigeria NCT03870061 | GiveWell | N/A |
| Completed | The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine NCT03931239 | Vabiotech | N/A |
| Unknown | Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan NCT03341195 | Aga Khan University | N/A |
| Withdrawn | Evaluation of Immunogenicity and Safety of DTPa-IPV/Hib Conjugate Vaccine (Infanrix™-IPV/Hib) Administered at NCT03128489 | GlaxoSmithKline | Phase 3 |
| Completed | A Study to Compare LBVD to Eupenta and Imovax Polio in Healthy Adults NCT03208101 | LG Chem | Phase 1 |
| Completed | Safety Monitoring of Boostagen® Vaccine in Thailand NCT07444502 | BioNet-Asia Co., Ltd. | — |
| Completed | To Evaluate the Immunogenicity and Safety of 'BR-TD-1001' Administered Intramuscularly in Healthy Children NCT04618939 | Boryung Biopharma Co., Ltd. | Phase 3 |
| Completed | Evaluation of Immunogenicity and Safety of a Booster Dose of Infanrix Hexa™ in Healthy Infants Born to Mothers NCT02853929 | GlaxoSmithKline | Phase 4 |
| Completed | A Study to Assess the Immunogenicity and Safety of GSK Biologicals' Infanrix-IPV/Hib Vaccine Administered as a NCT02858440 | GlaxoSmithKline | Phase 3 |
| Completed | A Post-marketing, Observational, Retrospective Study to Assess the Safety of RefortrixTM (Tdap) When Administe NCT02757950 | GlaxoSmithKline | — |
| Completed | DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infect NCT02817451 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Unknown | Safety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine NCT02813486 | Green Cross Corporation | Phase 1 / Phase 2 |
| Completed | Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, Uganda NCT04177485 | Centers for Disease Control and Prevention | N/A |
| Completed | Immunogenicity and Safety Study of Infanrix Hexa in Healthy Infants Born to Mothers Vaccinated With Boostrix™ NCT02422264 | GlaxoSmithKline | Phase 4 |
| Completed | Study of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed in Healthy Subjec NCT02587520 | Sanofi Pasteur, a Sanofi Company | Phase 1 / Phase 2 |
| Completed | Impact of Boostrix™ Maternal Vaccination on Morbidity and Mortality of Pertussis Disease in Infants ≤6 Weeks o NCT02569879 | GlaxoSmithKline | — |
| Completed | Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 NCT02428491 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Unknown | Post-authorization Safety Study of Euforvac-Hib Vaccine for Active Primary Immunization in Infants From 6 Week NCT02257645 | LG Life Sciences | — |
| Completed | Vaccine -diphthEria -tetaNus -Acellular pertUssis-inactivated polioviruS NCT02458183 | Boryung Pharmaceutical Co., Ltd | Phase 3 |
| Completed | Duration of Protection: GSK DTaP Vaccines NCT02447978 | GlaxoSmithKline | — |
| Completed | DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Ja NCT02274285 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 a NCT02096263 | GlaxoSmithKline | Phase 3 |
| Completed | Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents NCT02118961 | Tanabe Pharma Corporation | Phase 3 |
| Completed | DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed NCT02094833 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of SP306 Given Intramuscularly Compared to DT Given Subcutaneously in Japanese Adolescents 11 - 12 Years NCT02089347 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Safety of a Booster Dose of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Healthy Vietnamese Childre NCT01988857 | GlaxoSmithKline | Phase 3 |
| Completed | Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine in Indian Infants Previously Given a Dose of Hepatitis B Vaccin NCT01948193 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vac NCT01993173 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety of a Tetanus-diphtheria Vaccine and a 13-valent Pneumococcal Conjugate Vaccine NCT03552445 | Korea University Guro Hospital | Phase 4 |
| Completed | Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa NCT01983540 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Randomized Controlled Trial of the Impact of Mobile Phone Delivered Reminders and Travel Subsidies to Improve NCT01878435 | Johns Hopkins Bloomberg School of Public Health | N/A |
| Completed | A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject NCT01917357 | Crucell Holland BV | Phase 3 |
| Completed | Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China NCT01933776 | Sanofi Pasteur, a Sanofi Company | Phase 1 |
| Completed | Study to Analyze the Risk Factors Associated With Pertussis/Whooping Cough Infection Among Infants NCT01890850 | GlaxoSmithKline | — |
| Completed | Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Boostrix™ Vaccine in Previously Boosted Young NCT01738477 | GlaxoSmithKline | Phase 3 |
| Completed | Safety of GSK Biologicals' Infanrix-IPV+HibTM Vaccine in Healthy Vietnamese Toddlers NCT01577732 | GlaxoSmithKline | Phase 3 |
| Completed | Diphtheria Vaccination in Adolescents With Inflammatory Bowel Disease NCT03998215 | Medical University of Warsaw | N/A |
| Completed | Tdap Vaccine in Post-Partum Women NCT01711645 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 4 |
| Completed | Study of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine (ADACEL®) as a Booster in A NCT01689324 | Sanofi Pasteur, a Sanofi Company | Phase 1 / Phase 2 |
| Completed | Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age NCT01659996 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Immunogenicity of Adacel® and BOOSTRIX® Vaccines in Adolescents NCT01629589 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Post-marketing Surveillance to Assess the Safety of Infanrix-IPV Vaccine Among Infants and Children in Korea NCT01568060 | GlaxoSmithKline | — |
| Completed | Immunogenicity and Safety Study in Infants of GlaxoSmithKline Biologicals' Infanrix Hexa™ (DTPa-HBV-IPV/Hib) V NCT01353703 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vacci NCT01529645 | Novartis Vaccines | Phase 1 |
| Completed | Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE NCT01546909 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China NCT01491087 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Immunogenicity, Safety and Tolerability of a Fully Liquid Pentavalent (DTwP-Hib-Hep B) Vaccine in Infants 6-8 NCT01470287 | Novartis Vaccines | Phase 3 |
| Completed | Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose NCT01439165 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Safety and Immunogenicity of a Booster Dose of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/H NCT01453998 | GlaxoSmithKline | Phase 2 |
| Completed | Immunogenicity and Safety Study of Booster Dose of GSK Biologicals' IPV (Poliorix™) and DTPa/Hib (Infanrix+Hib NCT01449812 | GlaxoSmithKline | Phase 3 |
| Completed | Study of the Booster Effect of DTaP-IPV-Hep B-PRP~T Combined Vaccine or Infanrix Hexa™ and Prevenar™ in Health NCT01444781 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety of BoostrixTM Using a New Syringe in 10 to 15-year Old Adolescents NCT01362322 | GlaxoSmithKline | Phase 4 |
| Completed | Regulatory Post-Marketing Surveillance Study for TETRAXIM™ NCT01437423 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Study to Evaluate Antibody Persistence in Children Previously Vaccinated With Infanrix Hexa™ or Infanrix-IPV/H NCT01358825 | GlaxoSmithKline | Phase 4 |
| Completed | Study to Assess if Quinvaxem Can be Interchanged With Other Pentavalent Vaccines During Standard Childhood Vac NCT01357720 | Crucell Holland BV | Phase 4 |
| Completed | Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children NCT01245049 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of Booster Dose of BoostrixTM Polio Vaccine in Previously Boosted Adults NCT01323959 | GlaxoSmithKline | Phase 4 |
| Completed | Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age NCT01346293 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib Vaccine NCT01309646 | GlaxoSmithKline | Phase 3 |
| Completed | Study of Adacel® Vaccine Administered to Persons 10 Years of Age NCT01311557 | Sanofi | Phase 4 |
| Completed | Safety and Immunogenicity Study of a Diphtheria, Tetanus, Acellular Pertussis and Poliomyelitis Vaccine (REPEV NCT01287949 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Safety and Immunogenicity of New Formulations of GlaxoSmithKline Biologicals' DTPa-HBV-IPV/Hib Vaccine (GSK217 NCT01248884 | GlaxoSmithKline | Phase 2 |
| Completed | Safety and Immunogenicity Study of Concomitant Versus Non Concomitant Administration of a Diphtheria, Tetanus, NCT01249183 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of PENTAXIM™ Vaccine Versus TETRAXIM™ Vaccine Given With ACTHIB™ Vaccine in South Korean Infants. NCT01214889 | Sanofi | Phase 3 |
| Completed | Immunogenicity and Safety Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine Administered as a Booster NCT01171989 | GlaxoSmithKline | Phase 2 |
| Completed | A Study of DTaP-IPV-Hep B-PRP-T Vaccine Given With Prevenar™ and Rotarix™ in Healthy Latin American Infants NCT01177722 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Evaluation of Boostrix™10 Years After Previous Booster Vaccination NCT01147900 | GlaxoSmithKline | Phase 4 |
| Completed | Post Marketing Surveillance for ADACEL™ in South Korea NCT01137435 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants NCT01090453 | GlaxoSmithKline | Phase 2 |
| Completed | Study to Evaluate the Immunogenicity and Reactogenicity of a Booster Dose of GSK2036874A Vaccine in Healthy To NCT01106092 | GlaxoSmithKline | Phase 2 |
| Completed | Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by NCT01362517 | Crucell Holland BV | Phase 3 |
| Completed | Antibody Persistence in Healthy Children After Primary and Booster DTaP-IPV-Hep B-PRP-T Vaccine or Control Vac NCT01105559 | Sanofi | — |
| Completed | Immunogenicity and Safety Study of GSK Biologicals' Infanrix-IPV+Hib™ Vaccine NCT01086423 | GlaxoSmithKline | Phase 3 |
| Completed | A Study of DTaP//PRP-T Combined Vaccine (ACTACEL) Versus Local DTaP and Act-HIB Monovalent Vaccine in Healthy NCT01062477 | Sanofi | Phase 3 |
| Withdrawn | A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly NCT01003431 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | A Study to Assess the Safety of Adacel® Vaccine NCT01040052 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Safety Study of GSK Biologicals' DTPa-IPV/Hib (Infanrix™-IPV/Hib) NCT00964028 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of TETRAXIM™ Given as a Booster Dose at 4 to 6 Years of Age NCT01031303 | Sanofi | Phase 4 |
| Completed | Immunogenicity and Safety Study of GSK Biologicals' GSK2202083A Vaccine in Healthy Infants at 2, 3 and 4 Month NCT00970307 | GlaxoSmithKline | Phase 2 |
| Unknown | An Immunogenicity and Safety Study of Tetanus, Diphtheria and Acellular Pertussis Vaccine Booster NCT00870350 | Swedish Institute for Infectious Disease Control | Phase 4 |
| Terminated | Feasibility Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy Infants at 3, 5 and 11 Months NCT00871741 | GlaxoSmithKline | Phase 2 |
| Completed | Immunogenicity and Safety of Boostrix Polio Vaccine as a Booster Dose in 5 to 6-year-old Children. NCT00871000 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of Kinrix + (Measles Mumps Rubella) MMR Vaccine With and Without Varicella Vaccine i NCT00871117 | GlaxoSmithKline | Phase 3 |
| Completed | Evaluation of GlaxoSmithKline Biologicals' Boostrix® Vaccine in Comparison With Decavac™ Vaccine. NCT00835237 | GlaxoSmithKline | Phase 3 |
| Completed | Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease NCT00855855 | Sanofi Pasteur, a Sanofi Company | — |
| Unknown | Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine NCT00877357 | Shantha Biotechnics Limited | Phase 4 |
| Completed | Pertussis Vaccine in Healthy Pregnant Women NCT00707148 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Immunogenicity and Safety of Adacel Polio Vaccine NCT00797511 | Sanofi | Phase 3 |
| Completed | Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants NCT00753649 | GlaxoSmithKline | Phase 4 |
| Completed | Database Surveillance Safety Study of PENTACEL® Vaccine NCT00804284 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Immunogenicity and Safety of GSK Biologicals' Infanrix/Hib in Children NCT00696423 | GlaxoSmithKline | Phase 3 |
| Completed | Immune Responses in Adults to Revaccination With ADACEL® 10 Years After a Previous Dose NCT00712959 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Infanrix®Hexa in Healthy Peruvian Infants NCT00831753 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine NCT00617812 | Shantha Biotechnics Limited | Phase 4 |
| Completed | Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine NCT00674908 | Shantha Biotechnics Limited | Phase 4 |
| Completed | Study of the DTaP-IPV-Hep B-PRP~T Combined Vaccine Following a Primary Series of DTacP IPV-HepB-PRP-T or Infan NCT00654901 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study of a New Formulation of DTPa-HBV-IPV/Hib Vaccine Administered as a Booster Dose to 18-23 Months Old Chil NCT00611559 | GlaxoSmithKline | Phase 4 |
| Completed | Safety and Immunogenicity of a Booster Dose of GSK Biological's Boostrix-Polio Vaccine NCT00635128 | GlaxoSmithKline | Phase 4 |
| Completed | Immunogenicity and Reactogenicity of a Booster Dose of GSK Bio's DTPa-HBV-IPV/Hib Vaccine NCT00627458 | GlaxoSmithKline | Phase 2 |
| Completed | Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination. NCT00610168 | GlaxoSmithKline | Phase 4 |
| Completed | Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish NCT00619502 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058 NCT00548171 | GlaxoSmithKline | Phase 4 |
| Completed | Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB PRP~T Combined Vaccine in Filipino NCT00514709 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity Study of Antibody Persistence and Booster Effect of DTaP-HB-PRP~T Combined Vaccine or Tritanrix NCT00534833 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial NCT00489970 | GlaxoSmithKline | Phase 3 |
| Completed | Non-inferiority of GSK Biologicals' DTPw-HBV/Hib Compared to Two Formulations of GSK Biologicals' DTPw-HBV/Hib NCT00473668 | GlaxoSmithKline | Phase 3 |
| Completed | Pneumococcal Vaccine Booster Study in Healthy Children 11-18 Months Old Previously Primed With the Same Vaccin NCT00463437 | GlaxoSmithKline | Phase 3 |
| Completed | Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age NCT00467519 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine NCT00514059 | Norwegian Institute of Public Health | Phase 4 |
| Completed | Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine NCT00452686 | GlaxoSmithKline | Phase 3 |
| Unknown | Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease NCT00932269 | Swedish Institute for Infectious Disease Control | — |
| Completed | Immunogenicity and Safety of Pentaxim as 3 Doses Primary Vaccination Followed by a Booster Dose at 18 Months NCT00453570 | Sanofi | Phase 3 |
| Completed | A Trial to Evaluate the Safety and Immunogenicity of ADACEL® Vaccine in Persons 65 Years of Age and Older NCT00457249 | Sanofi | Phase 4 |
| Completed | REVAXIS® Versus DT Polio® as a Second Booster in 6 Year-old Children NCT00447525 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) NCT00432042 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Study to Assess Safety & Immunogenicity of GSK Biologicals' DTPa/Hib Vaccine vs Separate Administration of DTP NCT00412854 | GlaxoSmithKline | Phase 3 |
| Completed | Study to Assess the Safety & Reactogenicity of GSK Biologicals' dTpa Vaccine (Boostrix) When Given at 6-8 Year NCT00406562 | GlaxoSmithKline | Phase 3 |
| Completed | Lot Consistency Study of DTaP-IPV-HB-PRP~T Vaccine Administered at 2-4-6 Months of Age in Healthy Infants NCT00404651 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity, Safety of GSKs Tdap Vaccine Boostrix When Coadministered With GSKs Influenza Vaccine Fluarix i NCT00385255 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of a DTPa-HBV-IPV/Hib Vaccine Given at 2, 3 and 4 Months of Age NCT00376779 | GlaxoSmithKline | Phase 2 |
| Completed | Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL NCT00355121 | Sanofi | Phase 2 |
| Completed | Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai NCT00401531 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study to Assess the Safety & Reactogenicity of GSK Biologicals' DTPa/Hib Vaccine When Given at 3, 4 and 5 Mont NCT00379977 | GlaxoSmithKline | Phase 3 |
| Completed | Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Pr NCT00362427 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paedia NCT00362336 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Descriptive, Open-label, Multicenter Study of the Safety of Redosing With ADACEL® Vaccine NCT00347958 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Comparison of DTaP-HB-PRP~T Combined Vaccine to Tritanrix-HepB/Hib™, Both Given Concomitantly With Oral Polio NCT00343889 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years NCT00346073 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months NCT00315055 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Study to Compare Pediacel® to Infanrix®-IPV+Hib When Both Are Co-Administered With Prevenar® in Infants and To NCT00343421 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Safety of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared to Tritanrix-HepB/Hib™ and OPV Given at Age 2, 4, and NCT00313911 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Assess Immunogenicity, Reactogenicity, Safety of a Booster of GSK Biologicals DTPw-HBV/Hib Kft Compared to DTP NCT00332566 | GlaxoSmithKline | Phase 3 |
| Completed | Study Comparing a DTaP-HB-PRP~T Combined Vaccine With Tritanrix HepB/Hib™, Concomitantly With OPV in Healthy I NCT00348881 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and NCT00319553 | Sanofi | Phase 4 |
| Completed | Concomitant Use of Gardasil (V501, Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combin NCT00337428 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Concomitant Use of Gardasil (V501) (Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine) With Combi NCT00325130 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV NCT00319852 | Sanofi | Phase 3 |
| Completed | Compare Immunogenicity & Safety of 2 Formulations of GSK Biologicals' DTPa-HBV-IPV/Hib Vaccine Given in Health NCT00320463 | GlaxoSmithKline | Phase 3 |
| Completed | Post-marketing Evaluation of Reactions Following Receipt of Recommended Adolescent Pertussis Vaccine NCT00304265 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Terminated | Immuno & Safety Study With 2 Formulations of DTPw-HBV/HIB When Given at Birth With Hepatitis B at 2, 4 and 6 M NCT00316680 | GlaxoSmithKline | Phase 3 |
| Completed | Post-marketing Safety Study of GSK Biologicals' Boostrix® Vaccine NCT00297856 | GlaxoSmithKline | — |
| Completed | Immunogenicity Study of Antibody Persistence and Booster Effect of PENTAXIM™ at 18 Months in Healthy Argentine NCT00303316 | Sanofi | Phase 3 |
| Completed | Immunogenicity and Safety of Pentaxim™ in an Indian Population NCT00259337 | Sanofi | Phase 3 |
| Completed | Comparison of Safety and Immunogenicity of Pediacel™ and Infanrix™ IPV+Hib (Penta) Given in a 3 Dose Schedule NCT00287092 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infan NCT00197275 | GlaxoSmithKline | Phase 3 |
| Completed | US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococca NCT00282295 | GlaxoSmithKline | Phase 4 |
| Completed | Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m NCT00136604 | GlaxoSmithKline | Phase 3 |
| Completed | Evaluation of the Immunogenicity, Safety and Reactogenicity of the Combined DTPa-IPV Vaccine in Healthy Infant NCT00290342 | GlaxoSmithKline | Phase 3 |
| Completed | Immunology of Non-specific Effects of Vaccine NCT00168545 | Bandim Health Project | Phase 4 |
| Completed | Pentavalent DTaP-Hep B-IPV NCT00133445 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Immunogenicity and Safety of Sanofi Pasteur Pentaxim Combined Vaccine in Infants in Thailand NCT00255021 | Sanofi | Phase 4 |
| Completed | Immunogenicity & Safety of GSK's Combined DTPa-HBV-IPV/Hib Vaccine in Indian Infants at 2 Diff Vaccination Sch NCT00316147 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of ADACEL™ as Fifth Dose in Taiwan NCT00258908 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Multicentre Booster & Immune Memory Study of a Booster Dose of GSK Biologicals' 10-valent Pneumococcal Conjuga NCT00307567 | GlaxoSmithKline | Phase 2 |
| Completed | Safety and Immune Response of Different Pediatric Combination Vaccines. NCT00255047 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immunogenicity and Safety of Pentaxim in South African Infants NCT00254969 | Sanofi | Phase 3 |
| Completed | Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children NCT00228917 | GlaxoSmithKline | Phase 3 |
| Completed | Study of Menactra® in US Adolescents When Administered Concomitantly With Tdap Vaccine NCT00777257 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or NCT00258895 | Sanofi Pasteur, a Sanofi Company | Phase 3 |
| Completed | Immune Memory of DTPw-HBV/Hib Vaccine Following Primary Vaccination, Immuno & Reacto of a Booster Dose Given i NCT00169442 | GlaxoSmithKline | Phase 3 |
| Completed | Immune Response and Safety Comparison of 3 Lots of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP + IPV V NCT00148941 | GlaxoSmithKline | Phase 3 |
| Completed | Assess the Safety & Reactogenicity of DTPa-IPV/Hib Vaccine Administered at 3, 4, 5 & 18 Mths of Age, in Health NCT00325156 | GlaxoSmithKline | Phase 4 |
| Completed | Study of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® PEDIATRICO in Argentinea NCT00831311 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Assessment of the Reactogenicity of ADACEL® (TdcP Vaccine) in Children and Adolescents 7 to 19 Years of Age NCT00524732 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Immunogenicity & Safety Study of a Vaccine Against Meningitis in Infants (2,4,6 Months) After a Hepatitis B Bi NCT00317161 | GlaxoSmithKline | Phase 3 |
| Completed | Safety Study of a Vaccine Against Meningitis in Infants (2,4 & 6 Months Age) After a Birth Dose of Hepatitis B NCT00317187 | GlaxoSmithKline | Phase 3 |
| Completed | Assess if Immune Response of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Given Without or With Hepatitis B Vacc NCT00290303 | GlaxoSmithKline | Phase 3 |
| Completed | Canadian Manufactured Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine Compared With U.S. Manufactured Td NCT00601835 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ NCT00802867 | Sanofi Pasteur, a Sanofi Company | Phase 4 |
| Completed | Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 & 6 Months Age) After a Birth Dose of Hepatitis NCT00317135 | GlaxoSmithKline | Phase 3 |
| Completed | Safety of DTPa-IPV/Hib & DTPa-HBV-IPV/Hib, Followed by DTPa-IPV/Hib Vaccine in Infants Who Received Hepatitis NCT00325143 | GlaxoSmithKline | Phase 3 |
| Completed | Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunog NCT00263679 | GlaxoSmithKline | Phase 3 |
| Completed | Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™ NCT00772928 | Sanofi | Phase 3 |
| Completed | Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines NCT00254917 | Sanofi | Phase 4 |
| Completed | Comparison of Immunogenicity and Reactogenicity of INFANRIX™ HEXA and HEXAVAC™ Vaccines as a Primary Vaccinati NCT01457547 | GlaxoSmithKline | Phase 4 |
| Completed | Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months NCT00352963 | GlaxoSmithKline | Phase 3 |
| Completed | Retrospective Survey of Safety of Fourth Dose Pentacel® in Children NCT00772369 | Sanofi Pasteur, a Sanofi Company | — |
| Completed | Post Market Surveillance for Infanrix™ NCT00908115 | GlaxoSmithKline | — |
| Completed | A Study to Assess Antibody Persistence, Boostability & Safety in Previously Primed Subjects. NCT00317174 | GlaxoSmithKline | Phase 2 |
| Terminated | Immunogenicity, Antibody Persistence and Safety of GSK Biologicals' DTPa (INFANRIX) and dTpa (BOOSTRIX) Vaccin NCT00544271 | GlaxoSmithKline | Phase 4 |
| Completed | Post-marketing Safety Study of GSK Biological's Pediarix™ Vaccine NCT00146835 | GlaxoSmithKline | — |
| Completed | Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) NCT01294605 | GlaxoSmithKline | Phase 4 |
| Completed | Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in NCT00263692 | GlaxoSmithKline | Phase 2 |
| Completed | A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine NCT00109330 | GlaxoSmithKline | Phase 3 |
| Completed | Assess Immune Response Following Primary Vaccination With Tritanrix™-HepB Vaccine Mixed With 3 Formulations of NCT00291967 | GlaxoSmithKline | Phase 2 |
| Completed | Study of an Investigational Vaccine in Healthy Infants in Taiwan (V441-001)(COMPLETED) NCT00092469 | Merck Sharp & Dohme LLC | Phase 3 |
| Completed | Comparison of GSK Biologicals' Reduced Antigen Diphtheria and Tetanus Toxoids and Acellular Pertussis- Inactiv NCT01277705 | GlaxoSmithKline | Phase 3 |
| Completed | Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended NCT00662870 | Sanofi | Phase 3 |
| Completed | Immunogenicity and Reactogenicity of GSK Bio DTPa-HBV-IPV and Hib Vaccines When Coadministered to Healthy Infa NCT00879827 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib Vaccine Followed by the Same Vaccine and Oral Polio Vacc NCT01457560 | GlaxoSmithKline | Phase 3 |
| Completed | Study of Tetanus and Diphtheria Toxoids Adsorbed Combined With Component Pertussis Vaccine and Inactivated Pol NCT02040636 | Sanofi Pasteur, a Sanofi Company | Phase 2 |
| Completed | Immunogenicity and Reactogenicity of DTPa-HBV-IPV/Hib, Compared to DTPa-HBV-IPV and Hib Administered Separatel NCT01457508 | GlaxoSmithKline | Phase 3 |
| Completed | Immunogenicity and Safety of DTPa-HBV-IPV/Hib Compared to DTPa-IPV/Hib and HBV Administered Concomitantly NCT01457495 | GlaxoSmithKline | Phase 2 |
| Completed | Booster Study of Combined Diphtheria-tetanus-acellular Pertussis Vaccine in Healthy Adults NCT01267058 | GlaxoSmithKline | Phase 3 |
| Completed | Pilot Study Freeze and Transport Immune Cells NCT00138268 | National Institute of Allergy and Infectious Diseases (NIAID) | — |